We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Endothelin-1 as a Mediator of Heme Oxygenase-1-Induced Stemness in Colorectal Cancer: Influence of p53.
- Authors
Ríos-Arrabal, Sandra; Puentes-Pardo, Jose D.; Moreno-SanJuan, Sara; Szuba, Ágata; Casado, Jorge; García-Costela, María; Escudero-Feliu, Julia; Verbeni, Michela; Cano, Carlos; González-Puga, Cristina; Martín-Lagos Maldonado, Alicia; Carazo, Ángel; León, Josefa
- Abstract
Heme oxygenase-1 (HO-1) is an antioxidant protein implicated in tumor progression, metastasis, and resistance to therapy. Elevated HO-1 expression is associated with stemness in several types of cancer, although this aspect has not yet been studied in colorectal cancer (CRC). Using an in vitro model, we demonstrated that HO-1 overexpression regulates stemness and resistance to 5-FU treatment, regardless of p53. In samples from CRC patients, HO-1 and endothelin converting enzyme-1 (ECE-1) expression correlated significantly, and p53 had no influence on this result. Carbon monoxide (CO) activated the ECE-1/endothelin-1 (ET-1) pathway, which could account for the protumoral effects of HO-1 in p53 wild-type cells, as demonstrated after treatment with bosentan (an antagonist of both ETRA and ETRB endothelin-1 receptors). Surprisingly, in cells with a non-active p53 or a mutated p53 with gain-of-function, ECE-1-produced ET-1 acted as a protective molecule, since treatment with bosentan led to increased efficiency for spheres formation and percentage of cancer stem cells (CSCs) markers. In these cells, HO-1 could activate or inactivate certain unknown routes that could induce these contrary responses after treatment with bosentan in our cell model. However more research is warranted to confirm these results. Patients carrying tumors with a high expression of both HO-1 and ECE-1 and a non-wild-type p53 should be considered for HO-1 based-therapies instead of ET-1 antagonists-based ones.
- Subjects
COLORECTAL cancer; PREPROENDOTHELIN; HEME; ENDOTHELIN receptors; CANCER stem cells; TUMOR proteins
- Publication
Journal of Personalized Medicine, 2021, Vol 11, Issue 6, p509
- ISSN
2075-4426
- Publication type
Article
- DOI
10.3390/jpm11060509